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Abstract
Purpose: The aim of this study was to explore whether general practitioners (GPs) experienced barriers toward medication
reviews in polymedicated, multimorbid patients, and how a clinical pharmacologist with a focus on pharmacotherapy can support
the GPs in an outpatient clinic.
Design: The study was descriptive and exploratory and had a qualitative design with a phenomenological/hermeneutic orien-
tation for the interviews.
Participants: The study comprised 14 interviews with 14 different GPs from the Capital Region of Denmark.
Results: Three themes emerged from the interviews: (1) The care of patients With polypharmacy is challenged by the lack of
professional dialogue and collaboration between GPs and hospital-based clinical pharmacologists, (2) the relationship between the
patients with polypharmacy and the GP is characterized by care and individual considerations, and (3) the culture encourages
adding medication and inhibits dialogue about medication withdrawal even for patients with polypharmacy.
Conclusion and implications for practice: This study found that the primary barriers toward multimorbid patients with
polypharmacy were the need for communication and teamwork with specialists (cardiologists, neurologists, endocrinologists,
etc). Often, GPs felt that the specialists at the hospitals were more concerned about following standards and guidelines regarding
specific diseases instead of a more holistic patient approach. To improve management of polypharmacy patients, the GPs suggest
that a joint force is necessary, a partner-like relationship with greater transparency regarding information transfer, feedback, and
shared decision-making, but also more education in the pharmacological field is essential.
Keywords
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Background
Due to increasing longevity and widening diagnostic bound-
aries, the prevalence of people with more than one chronic
disease (ie, multimorbidity) is increasing.1,2 As the array of
pharmacologic treatments is also expanding, most multimorbid
patients are treated with polypharmacy, which can be defined
as the concomitant use of more than 2 drugs—often arbitrarily
set at a cutoff value of 5 or more.1,3 Polypharmacy is frequent
among elderly patients and is often associated with negative
health outcomes, greater economic burden, increased risk of
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hospital admissions, and mortality.4-6 Polymedicated elderly
patients are often treated with inappropriate medication. There-
fore, there is a great deal to gain from systematically perform-
ing critical reviews of multimorbid elderly patients’
medication. Ideally, a medication review that is carried out in
collaboration between a clinical pharmacologist, a physician,
and the patient could be beneficial for the elderly patient.4,7
Often, multimorbid, polymedicated patients attend multiple
outpatient clinics and are treated by several different special-
ists.2 Patients’ medications are often changed during visits to
the outpatient clinics and during hospital stay.8 In the Scandi-
navian countries, it is primarily the general practitioner (GP)
who renews the prescriptions for the patients. The Danish
health-care system provides free access to all health-care ser-
vices, including GPs, hospitals, and outpatient clinics. Further-
more, it provides partial compensation for prescribed
medications in order to ensure equal access to health services
for all citizens.9,10 This necessitates a close dialogue between
the primary and the secondary sectors—one which is often
lacking in the current system.1,2 Lack of communication may
result in negative health outcomes for the patients: physicians
and nurses may overlook adverse drug reactions and interac-
tions due to lack of knowledge of the patients’ combined
medication.1,3
During recent years, there has been an increased focus on
how health-care systems can benefit from improving cross-
sectoral collaboration, and how different concepts can be inte-
grated in order to improve health outcomes and create a more
effective use of health services and, at the same time, be eco-
nomically cost effective.11,12 Studies have shown that, through
a well-organized, cross-sectoral collaboration, it is possible to
establish more rewarding teamwork that can improve the
quality of treatments and ultimately benefit the patients.1,13
In the Scandinavian countries, the GPs function as gatekeepers
to the more specialized part of the health-care system, and they
are the primarily responsible persons for prescribing the ongoing
medical therapy. As such, they should have a full overview of
the patients’ diseases, family history, and medication.
Due to the increased prevalence of polymedicated patients,
the complexity of multiple diseases and their combinations,
sector transitions, and the financial framework for the public
health-care system, it is essential that the challenges are high-
lighted from a variety of perspectives. By focusing on the GPs,
we aim to gain knowledge about which quality improvements
are needed to ensure better and more effective treatment of
polymedicated, multimorbid patients.
The aim of this study was to explore whether GPs experi-
enced barriers toward medication reviews in polymedicated,
multimorbid patients, and how a dedicated clinical pharmacol-
ogist with a focus on pharmacotherapy could support the GPs
in an outpatient clinic.
Methods
The study was descriptive and explorative in nature and had a
qualitative design with a phenomenological/hermeneutic
orientation.14 We performed in-depth, face-to-face interviews
to capture the individual’s point of view, as each participant
experienced it, and to avoid influence by other participants.
The study was performed and reported according to the
consolidated criteria for reporting qualitative research
(COREQ) guidelines to describe important aspects of the
research and ensure reliability of the results.15
Participants
Participants were GPs from the Capital Region of Denmark.
The participants were recruited from 2 groups: an intervention
group and a nonintervention group. Participants in the inter-
vention group consisted of GPs with one or more patients who
had received a systematic medication review in the newly
established polypharmacy outpatient clinic (a collaborative
effort between the Department of Clinical Pharmacology and
the Department of Geriatrics). This intervention entailed a sys-
tematic medication review that was undertaken with the
patient’s GP before medication changes were effectuated in
collaboration with the patient in the polypharmacy outpatient
clinic. All interviews were performed during a 10-week period.
The GPs from both the intervention group and the usual care
group were contacted by phone. Sampling was promoted
through purposive sampling. Data saturation was reached when
no new themes emerged from the interviews.
Data Collection
The individual in-depth interviews were conducted at each
GP’s clinic in undisturbed surroundings. A semistructured
interview guide with open-ended questions was used. The
semistructured interview guide was based on the following
themes: (a) what barriers do GPs experience concerning poly-
pharmacy patients and optimisation of their medication and (b)
collaboration and communication between GPs and the physi-
cian at the hospital and the possible need for support from a
clinical pharmacologist with focus on pharmacotherapy. The
interviews were conducted by the first author (J.L.). The inter-
views lasted approximately 30 minutes or until the topic was
covered to the satisfaction of the participant and the inter-
viewer. The interviews were audio-taped and transcribed
verbatim.
Data Analysis
Content analysis was used to analyze the transcribed data.
Content analysis was chosen because it offers the authors a
flexible method for developing and extending knowledge of
the participants’ narratives.16 Two authors (J.L. and C.B.) ana-
lyzed the data according to the content analysis.16 The analysis
of the data was conducted in 2 parallel processes. The 2 authors
met to discuss their findings and agreed on the final themes.
The process was a back-and-forth reading of the text to con-
dense the data into different meaning units. These units were
then divided into subthemes. The subthemes were discussed
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until consensus was reached on the different themes by the 2
authors.16
Ethical Consideration
Participants were given information regarding the study, both
orally and in writing. They would provide a full oral and writ-
ten informed consent. Data were anonymized. The study was
approved by the Danish Data Protection Agency (2012-58-
0004). According to Danish law, ethical committee approval
is not needed for this type of study.
Findings
A total of 16 GPs were invited to participate of which 2
declined due to clinical obligations. Consequently, 14 GPs, 7
women with an average seniority (since specialization) of
15 years, median 14 years, participated in the study. Nine of
the GPs were in the intervention group. Three themes were
identified during the data analysis: (1) the treatment of patients
with polypharmacy is challenged by the lack of cross-sectoral
professional dialogue and collaboration with clinical pharma-
cologists; (2) the relationship between the patients with poly-
pharmacy and the GP is characterized by care and individual
considerations; and (3) the culture encourages further medica-
tion and inhibits dialogue about drug withdrawal for patients
with polypharmacy.
Theme 1: The Care of Patients With Polypharmacy is
Challenged by the Lack of Professional Dialogue and
Collaboration Between GPs and Hospital-Based Clinical
Pharmacologists
The GPs often felt that they were on their own when dealing
with the patients’ medication and that they were not able to get
in contact with the specialists at the hospitals. In most cases,
when a GP tried to contact a specialist at the hospital to discuss
a patient’s treatment, it was not possible to reach them, and it
was not uncommon that the youngest physician with limited
experience would answer the phone.
They often felt that there was a lack of teamwork between
sectors, which, for them, could only be seen as a frustrating
absence of dialogue with the specialists. The GPs describe
themselves as generalists and the physicians at the hospitals
as specialists; often, the GPs needed to discuss the patient’s
treatment because they did not feel they had the knowledge or
skills to make correct therapeutic decisions. As one GP stated,
“A specialized treatment belongs at the hospital, where the
specialist can use their expertise.”
The GPs often stated that they, as generalists, considered all
aspects of the patient. The GPs stated that patient-oriented care
(and not focusing only on disease) was very rare for the spe-
cialist at the hospital. The GPs indicated that the specialist’s
only focus was to follow standards and guidelines and that they
did not consider the patient’s age, competing diseases, contra-
indications and interactions due to polypharmacy, and so on
when planning the treatment. One GP claimed, “Guidelines can
only say so much about the disease and nothing about the whole
patient.”
When asked about barriers to medication withdrawal, the
GPs felt that they lacked the knowledge of how the drugs
interacted when there were more than 1 drug and that it was
their job to ensure the medication list was as accurate and up to
date as possible. It was clear that the GPs felt it was difficult to
discontinue medication that a specialist at the hospital had
prescribed. They were worried it would seem as if they did not
acknowledge the specialist’s work, and they knew that it would
be recommenced again at the next appointment in the outpati-
ent clinic. It was described as “If the medicine has been chan-
ged at the hospital, without you knowing why, it creates
uncertainty, because it may be medicine that I think is neces-
sary for the patient. Some specialists at the hospital only focus
on one illness, regardless of how it will transmit when the
patient gets home.”
In some cases, the GPs found that the treatment was becom-
ing increasingly specialized and that even the specialist had
difficulties deciding the right treatment, and it was therefore
often the GPs ended up deciding anyway. The GPs wanted a
dialogue with the specialist, and, if the theme was a medication
review, a clinical pharmacologist (clinical pharmacology is a
medical specialty in Denmark) was preferable. It did not neces-
sarily have to be in an outpatient clinic, but specialized support
was necessary.
The GPs found that there were discrepancies between the
systems in the different sectors and that they were not properly
informed about the changes made at the hospital. The ability to
communicate and enter into a dialogue with a specialist about
the patient was of very high priority. It was stated as: “Often we
are not informed about the changes. It is us, the GPs, that must
try and figure it all out, that isn’t easy.”
It was clear during the interviews that the GPs with the
largest number of multimorbid, polypharmacy patients were
also the most challenged by the lack of communication and
dialogue between sectors and specialists. However, all GPs
expressed a need for dialogue with a specialist. The GPs with
the largest number of patients with polypharmacy were also the
ones who described the cross-sectoral teamwork as the most
challenging.
Some of the participants wanted to have action cards, devel-
oped by clinical pharmacologists with a focus on pharma-
cotherapy, as a go-to list when they needed support during
discontinuation of medicine and when reviewing contraindica-
tions—some sort of an easy-access guideline. They also argued
for more education in more specific matters such as contra-
indications. There were no key differences between groups
(intervention and non-intervention) in our findings. The inter-
vention group was very positive regarding the medication
reviews at the outpatient clinic, whereas the nonintervention
group would have liked some kind of support by a clinical
pharmacologist for their multimorbid polymedicated patients.
There were only 2 GPs who did not see the need for this kind of
support, namely, the GPs with the fewest multimorbid patients
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and the ones who already felt they had a rewarding collaboration
with the specialist and clinical pharmacologist at the hospitals.
Theme 2: The Relationship Between Patients With
Polypharmacy and GP is Characterized by Care and
Individual Considerations
The GPs often perceived the relationship with their patients as
caring and trusting. The GPs prioritized the relationship with
patients and often described their concern toward their situa-
tion. The GPs often had a good knowledge of their patients and
their situation, they had often known the patients for several
years, and they knew their family and their situation in general.
This could be described as a barrier towards discontinuation of
medicine, despite the fact that the recommendations dictate that
they should be discontinued. One GP described it as: “The fact
that we have a personal relationship with our patients plays a
part when we discontinue medicine, especially when taking
sleeping pills and benzodiazepines, it is obvious that it does,
it’s difficult.”
The GPs describe a multimorbid, polymedicated patient as
an elderly patient with the same medication for many years,
and a patient who often finds great reassurance and comfort in
continuation of the usual amount of pills. Furthermore, the
patients did not always understand the GPs’ argument when
they try to discontinue some of their medication. The GPs felt
that they did not get anywhere and often had to postpone the
withdrawal. The GPs therefore argued that an external special-
ist such as a clinical pharmacologist with focus on pharma-
cotherapy may in some cases have greater success when
changing the list of prescriptions.
And if we’ve been talking to a patient for the past 3 years
about stopping a drug and they just think, ‘It’s just a stupid idea
my doctor has,’ but then if the clinical pharmacologist agrees
and explains it, they may appear more willing. But it requires a
dialogue. It could be by phone, in written, or personal meetings.
In the optimal world, it would be perfect if the specialist could
be more integrated in our daily work.
The GPs would, in some cases, even discontinue or continue
drugs that had been prescribed or deprescribed by a specialist,
even if the guidelines said otherwise. The argument was that
many studies do not include elderly, multimorbid patients, and
therefore there is no evidence that the drug has any effect on
these patients. As one GP argued:
You know what, when you are 85 years old you don’t have to
perform anymore and at the same time there is this ‘time to effect’,
that means, it takes more than 10 years before a patient at 85 is
getting a marginal effect, marginal!
The GPs’ consideration for the patient’s well-being was of
great concern. The GPs argued that, in some cases, it seemed as
if patients were poisoned, because each specialist followed
their own standards without noticing all other illnesses or the
patients’ general health. One GP described it as: “You some-
times find that they have become over-medicated, but
according to the various guidelines, you just have to do it. You
can’t really treat people like that, right?”
Theme 3: The Culture Encourages Further Medication
and Inhibits Dialogue About Medication Withdrawal
Even for Patients With Polypharmacy
The GPs felt that the medical profession in general is becoming
increasingly specialized and that each hospital-based specialist
only followed guidelines within their specific area and did not
consider other perspectives or illnesses when it came to med-
ication. The GPs felt that the organizational structure was inef-
fective; it did not allow time for dialogue or a way for them to
communicate about the multimorbid patients. Often, when the
patients experienced side effects due to a combination of drugs,
the problem had to be solved by the GPs. The GPs felt respon-
sible for something that they alone could not change. It was
described as:
“There are so many stakeholders and so many with their own
agendas, which can change the rhythm. So, I think communication
is always what turns out to be the best, but it must be cross-sectoral.
You need to be able to join forces more freely, getting hold of the
different stakeholders that are involved with the patient. I often
experience that it can be difficult.”
Often, GPs felt that the specialist at the hospital only added
more drugs to the patient’s medication list and they did not con-
sider whether the patient would actually obtain any benefit from
the extra medication or reflect on interactions and cumulative
adverse events due to the long medication list. One GP stated:
“Each hospital contact is only adding more drugs to the list.”
The GPs often described the organization of cross-sectoral
cooperation when treating multimorbid patients with polyphar-
macy as cumbersome and sluggish. They described that the
communication between sectors was slow and inadequate; it
could take weeks before they received any correspondence
about a patients’ medication. One GP expressed it as: “This
is a huge barrier, not being able to get hold of the different
stakeholders involved with the patient. I often experience that it
can be difficult. You need to be able to work more freely across
sectors and not be so limited.” Two GPs experienced fewer
barriers due to the fact that the communication flowed more
easily between sectors in their area; they did not meet the same
obstructions when calling the specialists at the hospitals, they
expressed it as: “It’s crucial that I can get a hold on the spe-
cialist, so I just have all the medical specialties on speed dial.”
However, all GPs expressed that easy access to a specialist at
the hospitals would facilitate better teamwork. When asked
about the polypharmacy clinic, the GPs were divided; they all
welcomed the initiative of having the support of a clinical
pharmacologist with focus on pharmacotherapy when optimiz-
ing the medication, but some of them would have preferred that
the dialogue was at the GPs’ clinic and not at another outpatient
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clinic. They were concerned that the dialogue would fade or be
weakened and that this would not break down the barriers
between sectors.
Because of the way the cross-sectoral collaboration is orga-
nized, the GPs felt that the health-care culture endorsed more
medication instead of less and that it was easier and less time
consuming to continue medication prescribed by the specialists
at the hospitals.
Discussion
The present study investigated GPs’ barriers toward medication
reviews in multimorbid, polymedicated patients and whether a
clinical pharmacologist with focus on pharmacotherapy in an
outpatient clinic can support the GPs’ work with these patients.
The ultimate goal was to identify areas where medical treat-
ment of multimorbid, polymedicated patients could be
improved. When GPs were asked about the medication review
process made, it was clear that they experienced barriers
toward deprescribing. The GPs often described that it was their
responsibility to keep track of the patient’s medication list,
regardless of how specialized the treatment was.
In this study, there was clearly an agreement among the GPs
about the different aspects that influenced the discontinuation
of drugs. The GPs felt that the fact that they knew their patients
well, and that, in some cases, knowledge had an impact on their
decisions when discontinuing medicine. In some cases, the GPs
felt ambiguity toward the discontinuation of certain drugs in
multimorbid patients. For the GPs, it was always an evaluation
of the patient’s resources in relation to what they could manage
regarding decisions about discontinuing drugs. It was impor-
tant for the GPs to make sure that the patients would not be
overwhelmed and felt pushed away. Previous studies have
found that GPs address patient issues and insecurity toward
decision-making when it comes to discontinuing drugs.17 One
study described 4 important aspects when GPs’ prescriptions
seemed inappropriate: (a) the need to please the patients, (b) a
feeling of being forced, (c) tension between experience and
guidelines, and (d) fear of prescribing.18 The need to please
the patient was often linked to the statement “the path of least
resistance” and that it was much quicker and easier to just
prescribe what the patient wanted. In some ways, this was
similar to what the GPs said in these interviews: The need to
please the patient was linked to the path of lesser resistance.
However, there is also an aspect of general care and a desire to
do what is best for the patient regardless of instructions and
guidelines; the GPs saw themselves as having a closer and
more holistic approach compared to the specialist at the hos-
pital. To care for others is fundamental and is often a basic
condition and a basis of treating patients.19 The gap between
the real world and the ideal treatment and the sense of doing
good or harm will often be challenging for the GPs. It has been
shown that empathy from health professionals is vital for the
patients, and GPs that do not show support and compassion will
affect the patients negatively, often leaving them anxious and
powerless.20,21
Various drugs are given at different times in the patients’
lives, often by a growing number of specialists, who prescribe
medications for specific problems in their field of expertise.22
Many GPs felt reluctant to change decisions made by special-
ists.22 Almost all clinical trials focus on testing the addition of
new medicine, and there are very few trials focusing on review-
ing medication lists or reducing or stopping medicines.23
Another argument was that very few studies include older
patients with comorbidity, and therefore there is no definitive
evidence of the effect and harm of the treatment.24,25 The GPs
argued that, for 85-year-old patients with polypharmacy, more
drugs would likely have a poorer effect, or the time to effect
would not be before the patient had already died. This is also
supported by other studies, where it has been argued that new
studies on drug effect must provide better information about
the recruitment process and that more attention should be paid
to the overall test results being more representative to the
broader population.24,25
Taken together, the interviews revealed a general under-
standing that—regardless of the various barriers—it was desir-
able and feasible to decrease the medication burden for elderly
patients with polypharmacy. A general standpoint was that the
GPs, as generalists, did not feel they had the necessary knowl-
edge or backup from hospital-based specialists to conduct crit-
ical medication reviews, and this highlighted the need for better
cross-sectoral collaboration as well as greater education. It was
clear through the interviews that GPs were interested in the
support from a clinical pharmacologist with focus on pharma-
cotherapy when discontinuing medication. An important state-
ment was that the GPs felt a need for more dialogue and a better
teamwork across sectors for the benefit of the patient. These
statements are in line with a study on factors influencing depre-
scribing; in this study, they argued for more education but also
highlighted the need for better conditions and better coopera-
tion between sectors.12,26
Limitations of the Study
We performed the study according to accepted principles for
in-depth interviews and design. The results were reported
according to the COREQ guidelines.15 The generalizability
of this study is limited by the fact that only Danish GPs were
interviewed, and the findings might only be applicable for Den-
mark or other countries with similar health-care systems, for
example, Scandinavian countries. The fact that the interviews
were related to a specific intervention (polypharmacy outpati-
ent clinic manned with clinical pharmacologists) may have
affected the GPs’ statements. However, this was the reason for
including GPs that had not received the intervention.
Conclusion and Implications for Practice
In conclusion, we found that the barriers toward multimorbid
patients with polypharmacy were primarily related to the lack
of relevant communication between sectors, and also the fact
that GPs felt a great deal of empathy with their patients, which,
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in some cases, could influence a medication review process,
and they suggested that a hospital-based specialist with a
focus on clinical pharmacology might relevantly support
this process. Often, GPs felt that the specialists at the
hospitals were more concerned with following guidelines
and instructions regarding the specific diseases, instead of
considering the whole patient. Many of the GPs experienced
that the culture encourages further prescriptions and inhibits
cross-sectional dialogue; this is an argument for the contin-
ued development of interventions, where the specialist and
the generalist work closer together.
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